- Ovation Science (CSE:OVAT) has signed a distribution agreement with Israel’s Gad Medical Equipment, for its DermSafe hand sanitiser
- Gad Medical is a medical distributor, which services all private and public hospitals in Israel
- Due to the COVID-19 pandemic, Gad Medical will ask Israel’s Ministry of Health to fast-track the review of DermSafe
- As of April 20, Israel had reported over 13,883 cases of the coronavirus, with 181 deaths
- Ovation Science’s share price is up 9.76 per cent, and is currently trading for $0.45 per share
Ovation Science (CSE:OVAT) has signed a distribution agreement with Israel’s Gad Medical Equipment, for its DermSafe hand sanitiser.
Gad Medical is an established medical distributor, based in Tel Aviv, Israel. The company imports and markets healthcare equipment, pharmaceuticals, and consumables for hospitals and clinics. Gad Medical’s clients include all of the private and public hospitals in Israel.
Worldwide, demand for hand sanitiser is still at an all-time high, because of the ongoing COVID-19 pandemic. To quickly meet this need, Gad Medical will ask Israel’s Ministry of Health to fast-track its review of DermSafe. After the sanitiser gains initial approval, it will undergo a complete final registration approval process, allowing long-term sales in Israel.
Ovation’s President, Terry Howlett, welcomed the distribution agreement, which will initiate DermSafe sales in Israel.
“Finding an effective alternative to alcohol-based hand sanitisers is fast becoming a requirement from our global customers. We have the solution for them with DermSafe.
“With the agreement now in place, Gad Medical will be seeking approval of DermSafe due to the COVID-19 pandemic, and ultimately full approval.
“Gad Medical is uniquely positioned in Israel to sell DermSafe, as they have an established distribution system to all medical professionals. They also currently sell other medical products, which contain disinfectant ingredients,” Terry said.
Gad Medical’s CEO, David Frances, also commented on the distribution agreement.
“We are pleased to be working with Ovation Science, and to secure a product that can help our communities during the COVID-19 pandemic. The demand for antiseptics in Israel is extremely high, and we are familiar with the outstanding benefits of chlorhexidine gluconate. Subject to Ministry of Health approval, we plan to offer DermSafe to our medical clients across Israel,” David said.
As of April 20, Israel had reported over 13,3883 cases of the coronavirus. This is a significant increase from just one month ago, when the country had only 433 cases. As of April 20, Israel had reported 181 fatalities caused by COVID-19.
The entirety of Israel’s population, which exceeds 8.79 million people, receives medical care from just 85 hospitals. The country also has over 2,000 private clinics, and 278 residential long-term care facilities.
Ovation Science’s share price is up 9.76 per cent, and trading for $0.45 per share, as of 11:42am EST.
